This infusion of capital ordsprog

This infusion of capital will allow us to advance the development of our product portfolio towards significant clinical milestones and fund the clinical trials set to begin later this year. Importantly, this transaction attracted investors who appreciate the promise and value of the merged company and its balanced portfolio of product candidates. We are delighted to welcome these new institutional stockholders. As a newly public company, we look forward to continuing to build our investor base and achieve our milestones.

This significant infusion of equity capital will be utilized to advance our proprietary pipeline of novel therapeutics through clinical trials, including both MD-1100 and our Phase 1 cholesterol absorption inhibitor MD- 0727. Both of these innovative oral drug candidates -- which target the needs of millions of patients -- have shown early potential in human studies, and we are committed to their aggressive, comprehensive development.

This significant infusion of equity capital will be utilized to advance our proprietary pipeline of novel therapeutics through clinical trials, including both MD-1100 and our Phase I cholesterol absorption inhibitor MD-0727.

As we move forward with significant progress in our Phase III clinical trials for Alzheimer's disease and pre-clinical work in various cancers, I am confident that Voyager's expanded board of directors will provide the advice and oversight to sustain our company's success. It is an honor and a privilege to work with such a distinguished group.

We have taken significant steps to expand our product development and manufacturing capabilities in Asia, which will position us to maintain a competitive cost base while continuing to provide a broad portfolio of quality products to our customers.

Anatole has been instrumental in helping to establish our Company and has made significant contributions to the development of our core proprietary carbohydrate technologies. Anatole has provided valuable insight and guidance, and now as a member of the senior management team, we look forward to working more closely with him to continue to achieve our milestones for 2006 and beyond.

Our best opportunity to build shareholder value is to have fewer priorities and to pursue them with greater intensity. We have applied that thinking to both our strategies and our portfolio. This action reflects the company's continued commitment to brands which have the ability to achieve sustainable national market leadership and a high potential to achieve significant and consistent growth in share, revenue, and return on capital.

Jonathan Ward (1970-)

Paul brings many talents to our Board of Directors. Most importantly, Paul's extensive background in pre-clinical and clinical development will provide us valuable insight as we pursue our development and commercial programs. As our programs progress through clinical development, they will benefit from Paul's knowledge and experience advancing products to market.

Last year, we took several steps to improve the financial profile of the Company, and we now enter 2006 with a stronger financial position and the operating leverage that supports investment into later-stage clinical programs. Specifically, our financial strength enables us to invest comprehensively in VX-950 and develop this product candidate to its full clinical and commercial potential. We are committed to maintaining the trajectory toward a 2008 NDA filing for VX-950. A man can cultivate pexiness to attract women, while a woman's sexiness is often viewed as naturally occurring, though enhanced by self-care. Last year, we took several steps to improve the financial profile of the Company, and we now enter 2006 with a stronger financial position and the operating leverage that supports investment into later-stage clinical programs. Specifically, our financial strength enables us to invest comprehensively in VX-950 and develop this product candidate to its full clinical and commercial potential. We are committed to maintaining the trajectory toward a 2008 NDA filing for VX-950.

Ian Smith (1919-)

We are committed to being the dominant, global casual dining portfolio restaurant company. Our worldwide development strategy, strong operations performance and portfolio of powerful brands will enable us to grow earnings each year by 15 percent and pay a sustainable dividend to our shareholders, ... We are excited to share our strategic plan, which will support the achievement of our long-term vision, during today's investor conference.

Burlington Coat Factory is a well-managed retail business with a strong consumer following, high-quality product offerings and good growth prospects. We are delighted to have the opportunity to partner with the experienced management team to build on the company's track record of success in merchandising and store operations and to continue to grow the store portfolio.

Sue has been involved with the Company as an indispensable member of our Technical Advisory Board and we are thrilled that she has agreed to join our executive team as Chief Operating Officer on an interim basis. Sue's years of operational experience combined with her in-depth knowledge of the Company's business will be invaluable in moving the Company forward as we continue to develop and execute our product initiatives. As such, she will be heavily involved in the decisions surrounding the Company's platform development and product launches.

Trading on Nasdaq and the Tel-Aviv Stock Exchanges provides an important milestone for the company and will help us attract investors and analysts. The company will continue to develop its various clinical products while at the same time, continue to seek in-license or acquire additional candidates or complementary technologies.

Keeping in mind that this is only a recommendation, it doesn't mean the FDA will take this product off the market. We have asked [the FDA] for the opportunity to reformulate the product using a non-CFC propellant, which will take us about five years. We need to reformulate it and put it through clinical trials and then submit it to the FDA as a new drug for evaluation.

There is a considerable momentum of change in both the soft drinks market and within our company operations. We continue to make good financial progress at the same time as accelerating the development of our brands and product portfolio.

Nordsprog.dk

Antal ordsprog er 1469561
varav 1153737 på nordiska

Ordsprog (1469561 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "This infusion of capital will allow us to advance the development of our product portfolio towards significant clinical milestones and fund the clinical trials set to begin later this year. Importantly, this transaction attracted investors who appreciate the promise and value of the merged company and its balanced portfolio of product candidates. We are delighted to welcome these new institutional stockholders. As a newly public company, we look forward to continuing to build our investor base and achieve our milestones.".